facebook twitter linkedin
news and events

This material was prepared by a third party towards Selvita S.A. with its registered office in Kraków (hereunder: “Selvita”). Within the scope which was not authorized by Selvita’s management board, the description of factual circumstances regarding the activities of Selvita, embodied in this material presents merely opinion of the third party, in particular with respect to presented opinions, predictions, appraisals and forecasts of the financial data and future activity of Selvita and its results.

Therefore, Selvita does not warrant consistency of this material with the actual and legal situation. Neither Selvita, members of its corporate bodies, employees nor its consultants shall bear any liability for validity of opinions, predictions, appraisals, forecasts and any other date embodied in this material as well as for consequences of actions of any reader made on a basis of this material, in particular for the investment decisions or any losses resulting from use of this material.

Readers of this material shall make its own assessment, whether opinions or forecasts embodied therein are credible and adequate, in particular taking into account their investment strategy and actual and legal situation. In particular they should consult it with their independent financial and investment advisors. None of the information presented in this material shall constitute investment, legal, accounting or tax advice or a statement that any investment strategy is accurate or adequate, considering the circumstances of the reader.

Furthermore date presented in this material shall not constitute an offer to sell or purchase any financial instruments nor an invite the make such offer. It shall not be also not deemed as a recommendation for investment in any financial instrument nor an advertisement of such instruments.



DISAGREE AGREE

News Releases

 

  • Krakow, Poland – 22 September 2016 - Selvita (WSE:SLV), the largest drug discovery company in Central and Eastern Europe, has signed a preliminary agreement to purchase a land property in Krakow, Poland, where it plans to build its future drug discovery laboratories.   The land property size is 1.4 hectares and located in a close...
  • Krakow, Poland - 31 August 2016 – Selvita, the largest drug discovery company in Central and Eastern Europe, has experienced a dynamic revenue growth in the first half of 2016. Net revenues from sales (excluding grants) amounted to PLN 22.7 MM, resulting in a 31.4% growth compared to H1 2015 when the net revenues (excl. grants) amounted to PLN...
  • Kraków, Poland, 18 August 2016 – Selvita (WSE:SLV), the largest drug discovery company in Central and Eastern Europe, has received an acceptance for its IND application from the U.S. Food and Drug Administration (FDA) for SEL24, the first compound to advance in clinical development from the company's internal discovery pipeline.   SEL24...
  • Krakow, 17 August 2016 - Selvita will participate and exhibit at the upcoming Pharma ChemOutsourcing 2016 conference, which will take place 19 - 21 September 2016, in The Hilton Hotel in Parsippany, NJ.   ChemOutsourcing is the largest USA-based API show attracting annually 700-800 chemists and business development personnel from the...
  • Kraków, Poland – 09 August 2016 – Selvita Inc., the US subsidiary of Selvita S.A., headquartered in Cambridge, MA, has initiated a medicinal chemistry collaboration with the University of California, San Francisco (UCSF).   The project will be conducted with the Institute for Neurodegenerative Diseases at UCSF. Within the scope of...
  • A pioneering new company based on Selvita research and utilizing novel immunological approaches to disease Edinburgh, Scotland, July 28, 2016: Epidarex Capital today announces the launch of Nodthera Limited, a new biotech company focused on the discovery and development of novel inhibitors of the NLRP3 inflammasome. Nodthera is based on world...
  • Kraków, Poland – June 06, 2016 – The European Lead Factory, a scientific consortium dedicated to supporting the discovery of innovative medicines, has selected the first drug target program from Poland, to perform high throughput screening. The selected drug target is a part of the oncology project developed by Selvita within its epigenetics...
  • Krakow, 27 May 2016 - Selvita S.A. (WSE: SLV), the largest drug discovery company in Central and Eastern Europe, will participate and present at the upcoming Annual BIO International Convention, taking place on June 6-9, 2016, at the Moscone Center in San Francisco, USA.   The presentation will be held by Ms. Magdalena Marciniak, Business...
  • Krakow, Poland - May 16, 2016 – Selvita, the largest drug discovery company in Central and Eastern Europe, has generated strong revenue growth in the first quarter of 2016. Net sales revenues (excluding grants) amounted to PLN 11.4 MM, as compared to PLN 8.4 MM in Q1 2015, indicating dynamics at the level of 35.6%.   The total revenues...
  • Do you ever wonder what work at Selvita looks like..? Do you want to know who we’re looking for and what we can offer our employees? That clip is perfectly right for you!  
  • Krakow, Poland - March 23, 2016 – Selvita, the largest drug discovery company in Central and Eastern Europe, has reported another year of a double digit revenue growth.   In 2015, the company has enjoyed strong growth of revenues, which amounted to PLN 55.7 MM, compared to PLN 41.3 MM in 2014, which indicates a 35% increase in operating...
  • San Bruno, CA – March 11, 2016 - Selvita, the largest drug discovery company in Central and Eastern Europe, has just opened its West Coast US office, located in San Bruno, CA. Selvita has initiated its US operations in September 2015, opening a fully-owned US subsidiary, Selvita Inc., headquartered in Cambridge, MA. Now the company is...
  •   Krakow, Poland – 4 February 2016 – Selvita (WSE:SLV), the largest drug discovery company in Central and Eastern Europe, has signed a contract for the lease of laboratory space in Poznan, Poland. The new site will be located at in the Wielkopolska Centre of Advanced Technologies and commence research activities in the summer of 2016....
  • Krakow, 1 February 2016 - Selvita S.A. (WSE: SLV), the largest drug discovery company in Central and Eastern Europe, today announced that Pawel Przewiezlikowski, Chief Executive Officer of the company, will present at the upcoming 18th Annual BIO CEO & Investor Conference, which will take place on February 8 - 9, at the Waldorf Astoria New...
  • Krakow, December 15, 2015 - Selvita, the largest drug discovery company in Central and Eastern Europe, announced today that its Cell and Molecular Biology Laboratory has been incorporated into the European network of laboratories EU NETVAL (European Union Network of Laboratories for the Validation of Alternative Methods;...
  • Krakow, Poland – December 10, 2015 - Selvita, the largest drug discovery company in Central and Eastern Europe, was awarded the European Rising Star Award in the prestigious European Small and Mid-Cap Awards competition, organized by the Federation of European Stock Exchanges (FESE) and the European Issuers Association, in collaboration with the...
  • Krakow, Poland – November 25, 2015 - Selvita, the largest drug discovery company in Central and Eastern Europe, engaged in the development of breakthrough oncology therapies, announced that data from its SEL24 oncology program is scheduled to be reported at the upcoming 57th ASH Annual Meeting & Exposition, which will take place 5 – 8...
  • Focus is to discover small molecule lead candidates for multiple oncology indications   Darmstadt, Germany, Krakow, Poland - November 2, 2015 – Merck, a leading science and technology company, announced today that its healthcare business has entered into a three-year collaboration to validate new therapeutic concepts in the field of...
  • Krakow, Poland, 24 September 2015 - Selvita, the largest drug discovery company in Central and Eastern Europe, is expanding its activity in the field of bioinformatics and personalized medicine. The new subsidiary, Ardigen, will take over Selvita current bioinformatics division activity with an aim of its further development and expansion....
  • The largest drug discovery company in Central and Eastern Europe opens offices in Cambridge, MA and San Bruno, CA CAMBRIDGE, MA – September 18, 2015 – Selvita, the largest drug discovery company in Central and Eastern Europe is establishing its first offices in the United States. Appreciating the importance of the U.S. biotechnology and...
  •   Cambridge, MA and Krakow, Poland, September 22, 2015 — H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision oncology treatments, and Selvita (PL: SLV), the largest drug discovery company in Central and Eastern Europe, announced today that they have extended their strategic...
  • Krakow, 22 October 2015 - Polish Prime Minister, Ewa Kopacz, currently touring the country on a pre-election tour, visited today Krakow, paying a visit to the Life Science Park where Selvita laboratories are located.    Mrs Kopacz was joined by Mrs Roza Thun, Member of the European Parliament for Poland, Mr. Rafał...
  • Kraków, 13 August 2015 - The first half-year of 2015 is the third consecutive six-month period in which the Selvita Group achieved an operating profit. This positive result is the effect of the continued profitable operations in both innovations and services.   In H1 2015 the Selvita Group recorded a 34% growth in revenues, from PLN...
  • Krakow, 31 March 2015 - Selvita (WSE:SLV), the largest drug discovery company in Central and Eastern Europe, announced today that it is commencing IND-enabling studies for SEL24 project, the company’s first oncology drug candidate.   SEL24 is a novel, orally-available small molecule, selective inhibitor of PIM and FLT3 kinases, with...
  • Cambridge, UK - Krakow, Poland - 05 May 2015 - Selvita (WSE: SLV), a global drug discovery company with offices in the US and Poland, is opening its first office in the United Kingdom. The office is based in Cambridge, considered to be one of the most significant biotechnology clusters in the world. The new office will be responsible for...
  • Krakow, 07 May 2015 - Selvita, a global drug discovery company engaged in the development of breakthrough oncology treatments and drug discovery services, was awarded the Economic Award of the President of Poland in the category Innovation.   The award was presented by the President of Poland, Mr. Bronislaw Komorowski during the Final Gala...
  • Krakow, 16 March 2015 - Selvita, global integrated drug discovery partner for the pharmaceutical and biotechnology industries with offices in Greater Boston Area and Krakow, Poland, announced today that it has expanded its portfolio of protein chemistry services.   Analysis, production and purification of recombinant proteins remain the...
  • Krakow, 20 February 2015 - Selvita is a proud sponsor of the upcoming 3rd Annual Biosimilars & Biobetters Congress which will take place in London, on 20-21 April 2015.   3rd Annual Biosimilars & Biobetters Congress is bringing together over 350 senior-level key opinion leaders working in the biologics sector.   The...
  • Cambridge, MA and Krakow, Poland, 7 November 2014 - Felicitex Therapeutics, a leader in the diagnostics and development of therapeutics for quiescent cancers, and Selvita (PL: SLV), the largest drug discovery company in Central and Eastern Europe, announced today that they have entered into a strategic collaboration to develop breakthrough...
  • Krakow, 09 October 2014 - Selvita, Poland-based integrated drug discovery partner for the pharmaceutical and biotechnology industry, has commenced a cooperation with the Pharmaceutical Research Institute from Warsaw, to provide the Institute with services in the field of ophthalmic products’ analysis.   The aim of the cooperation is to...
  • Kraków, 06 October 2014 - Selvita will participate in the upcoming BIO-Europe 2014 conference. The event will take place on 03-05 November 2014, in Frankfurt, Germany. Selvita will also hold a presentation during the BIO-Europe event, presenting in the Cancer category.   The presentation will take place on November 5, at 11:15 a.m., in...
  • Krakow, 03 September 2014 – Cresset, innovative provider of computational chemistry software and services, announced on September 02, 2014 in Cambridge, UK, that Selvita S.A. has licensed Cresset’s Forge and Spark. These applications provide extensive capabilities in SAR analysis, ligand-based molecular design and bioisosteric replacement....
  • Krakow, 26 August, 2014 - Selvita will participate in CPhI Worldwide 2014, one of the greatest pharmaceutical events this year. The exhibition will take place on 7 - 9 October 2014, in Paris, France.   Selvita will be located at the stand #1J58, in Hall 1.   CPhI Worldwide 2014, the world's leading pharmaceutical networking event,...
  • Krakow, 26 August 2014 -  Selvita will participate and present at the upcoming Drug Discovery USA Congress, which will be held on 21 - 22 October 2014, in Boston, USA.   Ms Andrea Gerken, MBA, Deputy Director Alliance Manager at H3 BiomedicineSelvita's together with Pawel Przewiezlikowski, Selvita's Chief Executive Officer,...
  • Krakow, 12 August 2014 - Selvita will participate and present at the upcoming first edition of the Bio Latin America Conference. The conference will take place in Rio de Janeiro, in Brazil, from 9 - 11 September 2014.   Dr Milosz Gruca, Selvita's Director of Biology Department will deliver a presentation during the conference. The...
  • Krakow, 13 August 2014 - Selvita will paticipate in the upcoming Fragment-Based Lead Discovery Conference, which will take place in Basel, Switzerland on 21 - 24 September 2014. FBLD Conference is the premiere fragment-based discovery conference for 2014 - organised by scientists for scientists.  To get in touch with Selvita delegates at...
  • Krakow, 08 August 2014 - Selvita, Polish biotechnology company engaged in the discovery and development of breakthrough medicines to treat CNS, oncology and autoimmune disorders, as well as drug discovery services, has announced today that data from its SEL24 oncology program is scheduled to be reported at the ASH Meeting on Lymphoma Biology...
  • Krakow, 04 August 2014 - Selvita will participate in the Nordic Life Science Days 2014, which will take place in Stockholm, Sweden, on 7-9 September 2014.   Nordic Life Science Days is the largest Life Science Partnering Conference in the Nordic region, organized by SwedenBIO, the Swedish Life Science Industry Organization, in co-operation...
  • Krakow, 8 May 2014 - Selvita will participate in the 5th Annual Discovery Partnerships 2014 conference, which will be held in Berlin, Germany in May 19-20, 2014. Discovery Partnerships forum is an exclusive meeting point for interviewing potential partners, for informing oneself regarding the latest trends and for better understanding what type...
  • Krakow, 9 April 2014 - Selvita will participate in Biomed Israel Innovation Conference, which will be held in Tel Aviv Fairgrounds, Israel in May 20-22, 2014. Previous conferences hosted over 7,000 industry players, engineers and scientists with approximately 1,500 participants from over 45 countries and an excess of 4,500 one-on-one meetings....
  • Krakow, 11th of February 2014 – Selvita signed an agreement with Jagiellonian University for the new oncology project supported by the grant funded by the National Centre for Research and Development. Selvita plays the role of a leader in this project. The aim of the project „New inhibitors of heme oxygenase-1 as potential anticancer...